Michael E Menefee

Michael E Menefee

UNVERIFIED PROFILE

Are you Michael E Menefee?   Register this Author

Register author
Michael E Menefee

Michael E Menefee

Publications by authors named "Michael E Menefee"

Are you Michael E Menefee?   Register this Author

12Publications

443Reads

49Profile Views

Cabozantinib As Salvage Therapy for Patients With Tyrosine Kinase Inhibitor-Refractory Differentiated Thyroid Cancer: Results of a Multicenter Phase II International Thyroid Oncology Group Trial.

J Clin Oncol 2017 Oct 17;35(29):3315-3321. Epub 2017 Aug 17.

Maria E. Cabanillas and Komal Shah, The University of Texas MD Anderson Cancer Center, Houston, TX; Jonas A. de Souza, University of Chicago Medical Center, Chicago, IL; Susan Geyer, University of South Florida, Tampa; Michael E. Menefee, Mayo Clinic Jacksonville, Jacksonville, FL; Lori J. Wirth, Massachusetts General Hospital, Boston, MA; Stephen V. Liu, MedStar Georgetown University Hospital; John Wright, National Cancer Institute, Washington, DC; and Manisha H. Shah, Ohio State University, Columbus, OH.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2017.73.0226
Publisher Site
http://dx.doi.org/10.1200/JCO.2017.73.0226DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5652872PMC
October 2017

Systemic therapeutic approaches to advanced thyroid cancers.

Am Soc Clin Oncol Educ Book 2012 :389-92

From the Division of Medical Oncology; Division of Endocrinology, Mayo Clinic Florida, Jacksonville, FL; Division of Medical Oncology, Mayo Clinic, Rochester, MN.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.14694/EdBook_AM.2012.32.389DOI Listing
April 2016

A multicenter phase 2 trial of pazopanib in metastatic and progressive medullary thyroid carcinoma: MC057H.

J Clin Endocrinol Metab 2014 May 25;99(5):1687-93. Epub 2014 Feb 25.

Division of Medical Oncology (K.C.B., J.R.M., J.R., K.S., J.K.B., K.P.W., C.R.I., C.E.), Division of Biomedical Statistics and Informatics (V.J.S.), Division of Endocrinology (J.C.M., B.M., I.H., V.F.), Mayo Clinic, Rochester, Minnesota 55905; Division of Endocrinology (R.C.S.), Division of Medical Oncology (W.J.M., M.E.M., C.B.), Mayo Clinic Florida, Jacksonville, Florida 32224; Division of Medical Oncology (N.K.), Mayo Clinic Arizona, Scottsdale, Arizona 85259; Carbone Cancer Center (A.M.T.), University of Wisconsin, Madison Wisconsin 53705; Minnesota Oncology Hematology (P.J.F.), PA, Minneapolis, Minnesota 55407; National University Hospital (C.G.), Singapore 119228; and Cancer Therapy Evaluation Program (P.H.), National Cancer Institute, Bethesda, Maryland 20892.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1210/jc.2013-3713DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4010705PMC
May 2014

Preclinical evaluation of the mTOR inhibitor, temsirolimus, in combination with the epothilone B analog, ixabepilone in renal cell carcinoma.

Am J Cancer Res 2013 14;3(4):390-401. Epub 2013 Aug 14.

Department of Cancer Biology, Mayo Clinic College of Medicine 4500 San Pablo Road, Jacksonville, Florida, 32224.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3744018PMC
August 2013

Profound hair and skin hypopigmentation in an African American woman treated with the multi-targeted tyrosine kinase inhibitor pazopanib.

J Clin Oncol 2010 Jul 1;28(19):e312-3. Epub 2010 Jun 1.

Endocrine Malignancies Disease Oriented Group, Mayo Clinic Comprehensive Cancer Center, Mayo Clinic, Rochester, MN, USA.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2009.26.4432
Publisher Site
http://dx.doi.org/10.1200/JCO.2009.26.4432DOI Listing
July 2010